These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25281264)
1. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents. Gerecitano J J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264 [TBL] [Abstract][Full Text] [Related]
2. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315 [TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556 [TBL] [Abstract][Full Text] [Related]
5. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943 [TBL] [Abstract][Full Text] [Related]
6. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088 [TBL] [Abstract][Full Text] [Related]
7. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791 [TBL] [Abstract][Full Text] [Related]
11. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918 [TBL] [Abstract][Full Text] [Related]
12. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568 [TBL] [Abstract][Full Text] [Related]
13. Nucleo-cytoplasmic transport as a therapeutic target of cancer. Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752 [TBL] [Abstract][Full Text] [Related]
14. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391 [TBL] [Abstract][Full Text] [Related]
15. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. Parikh K; Cang S; Sekhri A; Liu D J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614 [TBL] [Abstract][Full Text] [Related]
16. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525 [TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108 [TBL] [Abstract][Full Text] [Related]
19. XPO1-dependent nuclear export as a target for cancer therapy. Azizian NG; Li Y J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143 [TBL] [Abstract][Full Text] [Related]
20. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]